5jsf: Difference between revisions
No edit summary |
No edit summary |
||
Line 19: | Line 19: | ||
</div> | </div> | ||
<div class="pdbe-citations 5jsf" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 5jsf" style="background-color:#fffaf0;"></div> | ||
==See Also== | |||
*[[Hydroxysteroid dehydrogenase|Hydroxysteroid dehydrogenase]] | |||
== References == | == References == | ||
<references/> | <references/> |
Revision as of 06:40, 6 September 2017
Crystal structure of 17beta-hydroxysteroid dehydrogenase 14 S205 variant in complex with NAD.Crystal structure of 17beta-hydroxysteroid dehydrogenase 14 S205 variant in complex with NAD.
Structural highlights
Function[DHB14_HUMAN] Has NAD-dependent 17-beta-hydroxysteroid dehydrogenase activity. Converts oestradiol to oestrone. The physiological substrate is not known. Acts on oestradiol and 5-androstene-3-beta,17-beta-diol (in vitro).[1] Publication Abstract from PubMed17beta-HSD14 is a SDR enzyme able to oxidize estradiol and 5-androstenediol using NAD+. We determined the crystal structure of this human enzyme as the holo form and as ternary complexes with estrone and with the first potent, nonsteroidal inhibitor. The structures reveal a conical, rather large and lipophilic binding site and are the starting point for structure-based inhibitor design. The two natural variants (S205 and T205) were characterized and adopt a similar structure. New Insights into Human 17beta-Hydroxysteroid Dehydrogenase Type 14: First Crystal Structures in Complex with a Steroidal Ligand and with a Potent Nonsteroidal Inhibitor.,Bertoletti N, Braun F, Lepage M, Moller G, Adamski J, Heine A, Klebe G, Marchais-Oberwinkler S J Med Chem. 2016 Jul 12. PMID:27362750[2] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
|